| scholarly article | Q13442814 |
| P2093 | author name string | Scholz P | |
| Wilmanns W | |||
| Kolb HJ | |||
| Bosse D | |||
| Jehn U | |||
| Heinemann V | |||
| Debus A | |||
| Wachholz K | |||
| Kähny B | |||
| P2860 | cites work | Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial | Q31125591 |
| Amphotericin B: 30 years of clinical experience | Q34028160 | ||
| Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate | Q35244959 | ||
| Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics | Q35372178 | ||
| Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. | Q35537748 | ||
| Overview of liposomes | Q36930003 | ||
| Liposomes in haematology | Q36933701 | ||
| Amphotericin B Serum Concentrations During Therapy | Q37158997 | ||
| Administering amphotericin B--a practical approach | Q39134411 | ||
| Liposomes as carriers of antimicrobial agents | Q39661451 | ||
| Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice | Q39819915 | ||
| Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion | Q40286515 | ||
| Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential | Q40485546 | ||
| Treatment of systemic fungal infections with liposomal amphotericin B. | Q40769532 | ||
| Favorable outcome of invasive aspergillosis in patients with acute leukemia | Q40791575 | ||
| Amphotericin B therapy in an anephric patient | Q41029852 | ||
| Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents | Q43684984 | ||
| Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. | Q44423028 | ||
| Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans | Q54551814 | ||
| Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome) | Q67834947 | ||
| Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients | Q67834952 | ||
| Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections | Q68411770 | ||
| Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture | Q68560091 | ||
| Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells | Q71269909 | ||
| A pharmacologic guide to the clinical use of amphotericin B | Q71356323 | ||
| Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B | Q71710586 | ||
| Liposomal amphotericin B and continuous venous-venous haemofiltration | Q72196461 | ||
| Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice | Q72287401 | ||
| Distribution and activity of amphotericin B in humans | Q93617796 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| amphotericin B | Q412223 | ||
| P304 | page(s) | 1275-1280 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients | |
| P478 | volume | 41 |
| Q39614541 | A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis |
| Q34294886 | Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. |
| Q34294904 | Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? |
| Q30653666 | Antifungal drugs in the treatment of systemic candidiasis: susceptibility to antifungal drugs, drug resistance, pharmacological data |
| Q38653256 | Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs. |
| Q64070463 | Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B |
| Q30355939 | Clinical Translation of Nanomedicine. |
| Q43725025 | Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography |
| Q39472116 | Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. |
| Q33978188 | Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephr |
| Q45921108 | Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes. |
| Q39476255 | Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis |
| Q92446036 | Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy |
| Q36868273 | Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions |
| Q89675098 | Minimum concentration of Amphotericin B in serum according to the formulation, dose, and daily or prolonged intermittent therapeutic regimen |
| Q53589859 | Mucormycosis resulting in gastric perforation in a patient with acute myelogenous leukemia: report of a case. |
| Q36276845 | Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease |
| Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
| Q34113512 | Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans |
| Q64129113 | Polyene Antifungals |
| Q35666527 | Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients |
| Q36248701 | Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy |
| Q38937745 | Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis. |
| Q44573557 | Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis |
| Q83996843 | Successful use of combination antifungal therapy in the treatment of coccidioides meningitis |
Search more.